Join Growin Stock Community!

Ethos technologies inc.LIFE.US Overview

US StockFinancial Services
(No presentation for LIFE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LIFE AI Insights

LIFE Overall Performance

LIFE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LIFE Recent Performance

-4.46%

Ethos technologies inc.

26.30%

Avg of Sector

-1.22%

S&P500

LIFE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LIFE Key Information

LIFE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LIFE Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Price of LIFE

LIFE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LIFE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
7.46
METRIC
VALUE
vs. INDUSTRY
Gross Margin
58.55%
Net Margin
1487.81%
Revenue Growth (YoY)
-195.21%
Profit Growth (YoY)
-181.97%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
7.46
Gross Margin
58.55%
Net Margin
1487.81%
Revenue Growth (YoY)
-195.21%
Profit Growth (YoY)
-181.97%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is LIFE's latest earnings report released?

    The most recent financial report for Ethos technologies inc. (LIFE) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LIFE's short-term business performance and financial health. For the latest updates on LIFE's earnings releases, visit this page regularly.

  • How is LIFE's revenue growth?

    In the latest financial report, Ethos technologies inc. (LIFE) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LIFE have?

    As of the end of the reporting period, Ethos technologies inc. (LIFE) had total debt of 12.68M, with a debt ratio of 0.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LIFE have?

    At the end of the period, Ethos technologies inc. (LIFE) held Total Cash and Cash Equivalents of 17.22M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LIFE's EPS continuing to grow?

    According to the past four quarterly reports, Ethos technologies inc. (LIFE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LIFE?

    Ethos technologies inc. (LIFE)'s Free Cash Flow (FCF) for the period is 43.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 493.47% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LIFE?

    The latest valuation data shows Ethos technologies inc. (LIFE) has a Price-To-Earnings (PE) ratio of -1.94 and a Price/Earnings-To-Growth (PEG) ratio of 0.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.